Patents by Inventor Gerald Voss

Gerald Voss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL USE
    Publication number: 20090104229
    Abstract: The invention provides the use of a) an HIV Tat protein or polynucleotide; or b) an HIV Nef protein or polynucleotide; or c) an HIV Tat protein or polynucleotide linked to an HIV Nef protein or polynucleotide (Nef-Tat); and an HIV gp120 protein or polynucleotide in the manufacture of a vaccine for the prophylactic or therapeutic immunisation of humans against HIV.
    Type: Application
    Filed: May 8, 2008
    Publication date: April 23, 2009
    Inventor: Gerald VOSS
  • VACCINE
    Publication number: 20080199494
    Abstract: A vaccine formulation for the prevention or amelioration of HIV infection in humans is provided. The vaccine comprises an HIV antigen, especially a protein which comprises Nef and/or Tat of HIV, and an immunostimulatory CpG oligonucleotide. Methods for making the vaccine formulation of the invention are described. Patients may also be treated by pre-administration of the CpG oligonucleotide prior to administration of the HIV antigen.
    Type: Application
    Filed: May 14, 2007
    Publication date: August 21, 2008
    Inventors: Nathalie Garcon, Gerald Voss
  • VACCINES
    Publication number: 20080131464
    Abstract: A vaccine formulation for the prevention or amelioration of plasmodium infection in humans is provided. The vaccine comprises a malaria antigen, especially a protein which comprises a portion of the CS protein of P. falciparum fused in frame via a linear linker to the N-terminal of HBsAg, and an immunostimulatory CpG oligonucleotide. Methods for making the vaccine formulation of the invention are described. Patients may also be treated by pre-administration of the CpG oligonucleotide prior to administration of the malaria antigen.
    Type: Application
    Filed: November 5, 2007
    Publication date: June 5, 2008
    Inventors: Joseph COHEN, Nathalie Garcon, Gerald Voss
  • VACCINE COMPRISING GP120 AND NEF AND/OR TAT FOR THE IMMUNIZATION AGAINST HIV
    Publication number: 20080102085
    Abstract: Use of a) an HIV Tat protein or polynucleotide; or b) an HIV Nef protein or polynucleotide; or c) an HIV Tat protein or polynucleotide linked to an HIV Nef protein or polynucleotide; and an HIV gp120 protein or polynucleotide in the manufacture of a vaccine suitable for a prime-boost delivery for the prophylactic or therapeutic immunisation of humans against HIV, wherein the protein or polynucleotide is delivered via a bombardment approach.
    Type: Application
    Filed: October 18, 2007
    Publication date: May 1, 2008
    Inventors: Peter Ertl, John Tite, Catherine Van Wely, Gerald Voss
  • Recombinant merozoite protein-142 vaccine
    Patent number: 7306806
    Abstract: In this application is the expression and purification of a recombinant Plasmodium falciparum (3D7) MSP-142. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant MSP-142 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
    Type: Grant
    Filed: January 25, 2002
    Date of Patent: December 11, 2007
    Assignee: United States of America as represented by the Secretary of the Army
    Inventors: Jeffrey A. Lyon, Evelina Angov, Joe D. Cohen, Gerald Voss
  • Vaccine for Prevention and Treatment of Hiv-Infection
    Publication number: 20070243203
    Abstract: This invention relates to novel HIV polypeptide and polynucleotide fusions of Gag; Pol and Nef which are useful in immunogenic compositions and vaccines. The invention relates in particular to a polypeptide which comprises Nef or an immunogenic fragment thereof, and p17 Gag and/or p24 Gag or immunogenic fragments thereof, wherein when both p17 and p24 Gag are present there is at least one HIV antigen or immunogenic fragment between them. The polypeptide may also comprise Pol or RT or an immunogenic fragment thereof.
    Type: Application
    Filed: August 3, 2005
    Publication date: October 18, 2007
    Inventors: Helge Abrecht, Martine Delchambre, Martine Marchand, Nathalie Mathy, Philippe Jean Gervais Ghislain Permanne, Gerald Voss
  • Novel use
    Publication number: 20050266025
    Abstract: The invention provides the use of a) an HIV Tat protein or polynucleotide; or b) an HIV Nef protein or polynucleotide; or c) an HIV Tat protein or polynucleotide linked to an HIV Nef protein or polynucleotide (Nef-Tat); and an HIV gp120 protein or polynucleotide in the manufacture of a vaccine for the prophylactic or therapeutic immunisation of humans against HIV.
    Type: Application
    Filed: April 29, 2005
    Publication date: December 1, 2005
    Inventor: Gerald Voss
  • Vaccine comprising gp120 and nef and/or tat for the immunisation against hiv
    Publication number: 20050058657
    Abstract: Use of a) an HIV Tat protein or polynucleotide; or b) an HIV Nef protein or polynucleotide; or c) an HIV Tat protein or polynucleotide linked to an HIV Nef protein or polynucleotide: and an HIV gp 120 protein or polynucleotide in the manufacture of a vaccine suitable for a prime-boost delivery for the prophylactic or therapeutic immunisation of humans against HIV, wherein the protein or polynucleotide is delivered via a bombardment approach.
    Type: Application
    Filed: July 26, 2002
    Publication date: March 17, 2005
    Inventors: Peter Ertl, John Tite, Catherine Van Wely, Gerald Voss
  • Vaccines
    Publication number: 20050002958
    Abstract: A vaccine formulation for the prevention or amelioration of plasmodium infection in humans is provided. The vaccine comprises a malaria antigen, especially a protein which comprises a portion of the CS protein of P. falciparum fused in frame via a linear linker to the N-terminal of HBsAg, and an immunostimulatory CpG oligonucleotide. Methods for making the vaccine formulation of the invention are described. Patients may also be treated by pre-administration of the CpG oligonucleotide prior to administration of the malaria antigen.
    Type: Application
    Filed: February 27, 2004
    Publication date: January 6, 2005
    Inventors: Joseph Cohen, Nathalie Garcon, Gerald Voss
  • Novel composition
    Publication number: 20040131638
    Abstract: The present invention relates to a vaccine composition comprising at least one human immunodeficiency virus (HIV) antigen and either one or both of: i) at least one herpes simplex virus (HSV) antigen and ii) at least one human papillomavirus (HPV) antigen.
    Type: Application
    Filed: October 23, 2003
    Publication date: July 8, 2004
    Inventors: Serge Debrus, Nathalie Louise Mathy, Gerald Voss
  • Recombinant P. falciparum merozoite protein-142 vaccine
    Publication number: 20030161839
    Abstract: In this application is the expression and purification of a recombinant Plasmodium falciparum (3D7) MSP-142. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant MSP-142 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
    Type: Application
    Filed: January 25, 2002
    Publication date: August 28, 2003
    Inventors: Jeffrey A. Lyon, Evelina Angov, Joe D. Cohen, Gerald Voss
  • Vaccine for the prophylactic or therapeutic immunization against hiv
    Publication number: 20030158134
    Abstract: The invention provides the use of a) an HIV Tat protein or polynucleotide; or b) an HIV Nef protein or polynucleotide; or c) an HIV Tat protein or polynucleotide linked to an HIV Nef protein or polynucleotide (Nef-Tat); and an HIV gpl20 protein or polynucleotide in the manufacture of a vaccine for the prophylactic or therapeutic immunisation of humans against HIV.
    Type: Application
    Filed: July 31, 2002
    Publication date: August 21, 2003
    Inventor: Gerald Voss